Long non-coding RNA LINC01224 promotes cell proliferation and inhibits apoptosis by regulating AKT3 expression via targeting miR-485-5p in endometrial carcinoma

XIN ZUO*, WEILING LI*, XIAOFANG YAN†, TIELIANG MA, YAN REN, MEIJUAN HUA, HUIYUN YANG, HAIFENG WU and HONGDI ZHU

Department of Obstetrics and Gynecology, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu 214200, P.R. China

Received August 5, 2020; Accepted May 20, 2021

DOI: 10.3892/or.2021.8137

Abstract. Endometrial carcinoma (EC) is the most common cancer in women worldwide, yet little is known about the underlying molecular basis of EC development. LINC01224, a novel long non-coding (lnc)RNA, was recently identified as an oncogene in various types of cancer. However, the function and underlying mechanism of LINC01224 in EC is still unclear. A total of 50 pairs of tumor and adjacent normal tissue from patients with EC, three EC cell lines and one human normal endometrial stromal cell (ESC) line were subjected to reverse transcription-quantitative PCR assay to evaluate the expression levels of LINC01224. Cell Counting Kit-8, colony formation and flow cytometry assays were used to assess cell proliferation and apoptosis. Western blotting was used to measure expression levels of apoptosis- and proliferation-associated proteins and AKT3 protein. A xenograft model of HEC1A cells was established to validate the in vivo function of LINC01224 in EC tumor growth. Starbase 3.0 database prediction and luciferase reporter and RNA pull-down assays were performed to verify the binding sites between LINC01224 and microRNA (miR)-485-5p and AKT3. LINC01224 expression was significantly upregulated in both EC tumor tissue and cell lines. The upregulation of LINC01224 was negatively associated with survival of patients with EC. Functionally, LINC01224 promoted proliferation and inhibited apoptosis of EC cells; LINC01224 directly bound to and downregulated miR-485-5p to elevate the expression levels of AKT3, thereby promoting EC progression. LINC01224 depletion in EC cells hindered tumor growth in a xenograft model. The tumor suppressing effect of LINC01224-knockdown on EC progression was partly rescued by treatment with miR-485-5p inhibitor. The present data demonstrated the expression levels, clinical relevance and functional mechanism of LINC01224 in EC. LINC01224 expression was promoted EC development via sponging miR-485-5p to elevate AKT3 expression levels; this may provide a promising therapeutic target pathway for EC treatment.

Introduction

Endometrial carcinoma (EC) is the sixth most common malignancy of the female genital tract worldwide, with 380,000 new cases in 2018 (1-3). Despite improvements in EC diagnosis and treatment, the prognosis and survival rate of patients with EC is still unsatisfactory due to invasion and recurrence, with >89,000 deaths in 2018 (2,3). Therefore, it is necessary to discover the underlying mechanism of the tumorigenesis of EC to develop novel biomarkers and improve therapy for patients with EC.

Long non-coding (lnc)RNAs are a group of ncRNAs >200 nucleotides in length that affect key biological processes, including transcriptional regulation, protein translation and degradation (4,5). Novel lncRNAs have been discovered and identified as crucial regulators involved in neoplastic tumorigenesis and development, such as tumor promoter lncRNA Xist, lncRNA HOTAIR and tumor suppressor lncRNA MEG3, TDRG1 (6-10), offering the possibility of lncRNAs as effective biomarkers and therapeutic targets for cancer. However, the association between the deregulation of lncRNAs and carcinogenesis remains unknown (5,11). Thus, identification of new lncRNAs not only provides insight into their functional roles.
but may also elucidate the potential mechanism of IncRNAs in human cancer, including EC.

Recently, LINC01224, a cancer-associated IncRNA, has been identified to be involved in carcinogenesis and to promote tumor proliferation, invasion, migration and apoptosis; its upregulation is associated with tumor grade and poor prognosis in epithelial ovarian cancer and hepatocellular carcinoma (12,13). However, the role and underlying molecular mechanism of LINC01224 in EC remains unclear. MicroRNAs (miRNAs/miRs) are short non-protein-coding RNAs ~22 nucleotides in length that inhibit gene expression by targeting the 3′-untranslated region (UTR) of mRNA. Accumulating evidence has demonstrated that miRNAs serve crucial roles in multiple biological processes, including cell growth, differentiation and apoptosis (14,15). IncRNAs serve as competing endogenous RNAs by sponging miRNAs, thus restoring miRNA-induced functions of target genes (6,16). Moreover, it has been reported that LINC01224 promotes epithelial ovarian cancer progression via sponging certain miRNAs and LINC01224 inhibits hepatocellular carcinoma progression via sponging miR-330-5p (12,13). However, whether LINC01224 interacts with miRNA in EC remains to be determined. Therefore, discovering the novel IncRNA-miRNA axis in EC is urgent for the identification of promising diagnostic biomarkers and therapeutic targets for EC treatment.

LINC01224 expression levels in EC tumor tissue and cell lines, and its association with survival of patients with EC, were assessed. The phenotypes of LINC01224 knockdown both in vitro and in vivo were also determined. The present study aimed to investigate the functional mechanism and clinical significance of LINC01224 in EC.

Materials and methods

Clinical patient samples. A total of 50 pairs of EC and adjacent (distance, ≥3 cm) para-carcinoma tissue samples were obtained from the Affiliated Yixing Hospital of Jiangsu University (Yixing, China). A total of 50 female patients (age, 42-68 years) were enrolled from January 2017 to January 2019. Patients were diagnosed with primary EC by two pathologists and had not received any therapy before sample collection. The tissues were instantly placed into liquid nitrogen to protect RNA integrity and stored at -80˚C for further use. All patient sample collections and experiments were approved by the ethics committee of the Affiliated Yixing Hospital of Jiangsu University and performed in accordance with the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all patients.

Cell lines. The human endometrial stromal cell (ESC) line, CL0453, was provided by Cell Bank of Chinese Academy of Sciences (cat. no. NBCC267006; Shanghai, China). Three EC cell lines (HEC1A, HEC1B and Ishikawa) and 293T cells were purchased from American Type Culture Collection (ATCC). Human ESC cells were cultured according to the protocol of the Cell Bank of Chinese Academy of Sciences [1:1 DMEM and Ham’s F-12 medium (both Gibco; Thermo Fisher Scientific, Inc.) supplemented with 2.0 mM L-Alanyl-L-Glutamine, 0.1 mM non-essential amino acids, 0.1 mM 2-mercaptopethanol and 4 ng/ml basic fibroblastic growth factor; 5% knockout serum replacement (Gibco; Thermo Fisher Scientific, Inc.) and 15% fetal bovine serum]; HEC1A cell line was cultured in McCoy’s 5A medium (Gibco; Thermo Fisher Scientific, Inc.); 293T, HEC1B and Ishikawa cell lines were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% (v/v) FBS (Gibco; Thermo Fisher Scientific, Inc.). All cell lines were cultured in a humidified 37˚C incubator with 5% CO₂.

Cell infection. To knock down the expression of LINC01224 in EC cells, a lentiviral short hairpin (sh)RNA vector targeting shLINC01224 was generated by inserting double-stranded oligonucleotides (shLINC01224#1, 5′-GGT TGGTGGCTCTTACGTCTGG-3'; shLINC01224#2, 5′-GCT TCTAGTCTGGTGGAA-3') into pLKO.1-puro Vector (Thermo Fisher Scientific, Inc.) plasmids (plKO.1-shRNA, 1 µg; pCMV-AR8.2, 1 µg; pMD2.G, 0.5 µg/per well in 6-well plates). Specific LINC01244 shRNA lentivirus was infected with HEC1A and Ishikawa cell lines for 48 h (Shanghai GenePharma Co., Ltd.). A total of 1×10⁵ HEC1A and Ishikawa cells were seeded in 6-well plates and incubated for 24 h at 37˚C and 5% CO₂. For the negative control (con) group, cells were added with lentivirus containing scramble shRNA (sh-con); for the LINC01244 knockdown group, cells were added with lentivirus containing shLINC01224#1 and shLINC01224#2. The stably infected cells were screened using puromycin (2 µg/ml) for 10 days.

Reverse transcription-quantitative (RT-q)PCR. Total RNA from HEC1A, HEC1B and Ishikawa cells was extracted following transfection using a miRNeasy Mini kit (cat. no. 217004; Qiagen GmbH). The first-strand cDNA was reverse transcribed using PrimeScript™ RT Master Mix (cat. no. RR036Q, Takara Bio, Inc.) according to manufacturer's protocol. RT-qPCR was performed using SYBR Green SuperMix (Roche Diagnostics) following the manufacturer's protocols. GAPDH and U6 were used as the internal control for IncRNA/mRNA and miRNAs, respectively. Each sample was run in triplicate using samples from independent experiments. The relative mRNA expression levels were expressed as a function of threshold cycle (Cq) and analyzed by the 2-ΔΔCq method (17). The primer sequences were as follows: LINC01224 forward, 5′-AGAGCTTTGGATCTTGCTTCTG-3′ and reverse, 5′-TTACTCTAGGTGCTCTTCCAC-3′; miR-485-5p forward, 5′-AGAGGCCCTGGCGGTGAT-3′ and reverse, 5′-ATGGTG TGCTGTGTTTTGTCG-3′; GAPDH forward, 5′-TATCTGT GATGCTAGTCCGTAG-3′ and reverse, 5′-TGCAAGCTG CTGCGATGCGCGG-3′ and U6 forward, 5′-CTCGTCTTG GCACACA-3′ and reverse, 5′-AACGCTTACGAATTTGC GT-3′. The thermocycling conditions were as follows: 95˚C for 15 min, followed by 95˚C for 30 sec, 65˚C for 30 sec and 72˚C for 30 sec (35-45 cycles) and 72˚C for 5 min.

Cell counting kit (CCK)-8 assay. Cell proliferation was evaluated by CCK-8 assay (Dojindo Molecular Technologies, Inc.) following the manufacturer's protocol. The transfected HEC1A
and Ishikawa cells were seeded at a density of 2x10^5/well in 96-well plates. Cells were cultured for 24, 48, 72 or 96 h at 37°C with 5% CO_2. Then, 10 µl CCK-8 solution was added to each well and incubated for 1 h at 37°C. The absorbance was measured at 450 nm with a microplate reader (Synergy H4 Hybrid Reader; BioTek Instruments, Inc.). Data are presented as the mean ± SD of three independent experiments.

Colony formation. A total of 1,000-1,500 cells were seeded into 6-well plates. After culturing for 14 days in a humidified 37°C incubator with 5% CO_2, the colonies were fixed with 10% formaldehyde for 30 min at room temperature and then stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) for 30 min at room temperature. The colonies were photographed under a light microscope at x20 magnification (Olympus Corporation).

Apoptosis assay. Transfected HEC1A and Ishikawa cells were seeded in a 6-well plate (1x10^4 cells/well). Following transfection, cells were harvested by centrifugation at 200 x g for 5 min at room temperature and washed with 1X PBS three times, then incubated with 5 µl FITC-conjugated Annexin V and 5 µl PI (25 µg/ml) (both BD Biosciences) for 15 min at room temperature in the dark. The stained cells were detected using a BD FACSAria II flow cytometer (BD Biosciences). FlowJo V10.5.2 (BD Biosciences) software was used to analyze data.

Western blot analysis. Transfected HEC1A and Ishikawa cells were lysed in RIPA buffer (Beyotime Institute of Biotechnology). Total protein concentration was qualified with a BCA Protein Assay kit (Sangon Biotech Co., Ltd.). Next, protein samples (~1,000 ng/lane) were separated with a BCA Protein Assay kit (Sangon Biotech Co., Ltd.). Total protein concentration was qualified with a BCA Protein Assay kit (Sangon Biotech Co., Ltd.). Western blot analysis was performed on 12% SDS-PAGE and transferred to PVDF membranes (MilliporeSigma). After blocking with 5% non-fat milk for 1 h at room temperature, the membranes were incubated with primary antibodies [cleaved caspase-3, 1:500, cat. no. ab32042; Bcl-2, 1:1,000, cat. no. ab32214; proliferating cell nuclear antigen (PCNA), 1:1,000, cat. no. ab292; AKT3, 1:2,000, cat. no. ab152157; β-actin, 1:5,000, cat. no. ab6276] at 4˚C overnight. Anti-rabbit (cat. no. ab150177, for cleaved caspase-3, Bcl-2, AKT3, β-actin) and anti-mouse IgG (cat. no. ab150113, 1:10,000, for PCNA) were used as the secondary antibody to room temperature for 2 h. All the antibodies were purchased from Abcam (Shanghai, China). ECL kit (Sangon Biotech Co., Ltd.) was used for chemiluminescent detection of immobilized proteins according to the manufacturer protocol. All antibodies were obtained from Abcam. The protein bands were quantified with ImageJ V1.8.0 software (National Institutes of Health).

Tumor xenograft experiments. A total of 12 female BALB/c nude mice (age, 4 weeks; weight, 13-15 g; Shanghai Model Organisms Center, Inc.) were used for xenograft experiments. All mice were housed in 25°C, 50% humidity and specific-pathogen-free conditions with a 12/12-h light/dark cycle. Sterile food and water were provided daily. All animal protocols were approved by the Institutional Animal Care and Use Committee at the Affiliated Yixing Hospital of Jiangsu University. Briefly, lentivirus-transfected HEC1A cells (1x10^4) were resuspended in 100 µl DMEM (Gibco; Thermo Fisher Scientific, Inc.) without FBS and subcutaneously injected into the flank of mice. After ~1 week, the tumor was visible (100 mm^3) and injected with sh-con, shLINC01224#1 and shLINC01224#2 (10 nmol/20 g) twice per week (n=6/group). Tumor volumes were measured every 7 days. Tumor volume was calculated as follows: Tumor volume (mm^3) = (height) x (width)^2/2. After 28 days, mice were sacrificed for analysis and tumor weight was measured. An intraperitoneal injection of 150 mg/kg pentobarbital was used for euthanasia. The dose of pentobarbital used for anesthesia was 10% in saline, 50 mg/kg, via intraperitoneal injection. Cessation of movement, breathing, and heartbeat were considered to indicate death. Mouse death was verified by cutting the chest cavity to confirm no heartbeat and touching the eyeball, which produced no reflex activity. Based on Institutional Animal Care and Use Committee guidelines, tumor size >20 mm at the largest diameter was considered to be the humane endpoint (18). After 28 days, the maximum tumor weight observed was 7.8% of mouse body weight. The maximum tumor diameter observed was 17.5 mm.

Luciferase reporter assay. The day before transfection, 293T cells were plated in 24-well plates (4x10^4 cells/well). Full-length LINC01224 gene and 3'-UTR of the AKT3 gene were cloned into pmirGLO plasmids containing luciferase (PromegaCorporation) according to the manufacturer's protocol and transfected into 293T cells. GeneArt™ Site-Directed Mutagenesis system (Thermo Fisher Scientific, Inc.) was used to produce the mutant (MUT) LINC01224 and AKT3 gene reporter. LINC01224 wild-type (WT)/MUT or AKT3 WT/MUT plasmids were co-transfected with miR-negative control (NC) or miR-485-5p mimics into 293T cells. GeneArt™ Site-Directed Mutagenesis system (Thermo Fisher Scientific, Inc.) was used to produce the mutant (MUT) LINC01224 and AKT3 gene reporter. LINC01224 wild-type (WT)/MUT or AKT3 WT/MUT plasmids were co-transfected with miR-negative control (NC) or miR-485-5p mimics into 293T cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions for 48 h. Following transfection for 48 h, luciferase activity was measured immediately by Dual-Luciferase Reporter Assay system (Promega Corporation) following the manufacturer's protocol, and firefly luciferase activity was normalized against Renilla luciferase activity.

Bioinformatics analysis. Gene Expression Profiling Interactive Analysis (GEPIA2; gepia2.cancer-pku.cn/#index) was used to analyze LINC01224 expression levels in EC. StarBase 3.0 (starbase.sysu.edu.cn/) was used to predict the interaction between LINC01224 and miRNAs and the targets of miR-485-5p.

RNA pull-down assay. LINC01224 and NC sequence (nonsense sequence) were biotin-labeled using Biotin RNA Labeling Mix and T7/SP6 RNA polymerase (Roche Diagnostics) to create bio-LINC01224 and bio-NC by Shanghai GenePharma Co., Ltd. by using pcDNA 3.1 (GenePharma Co., Ltd., China) with T7 promoter, according to the manufacturer's protocol. Following transfection, HEC1A and Ishikawa cell lines were lysed by lysis buffer (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol and incubated with biotinylated RNAs for 48 h at room temperature under moderate agitation on a tube rotator. Next, 200 µl lysed cells were collected and incubated with 400 µl Streptavidin
LINC01224 promotes proliferation and inhibits apoptosis of EC cells. To investigate the functional role of LINC01224 in EC, loss of function experiments were performed using HEC1A and Ishikawa cell lines with high LINC01224 expression. Firstly, LINC01224 was knocked down in HEC1A and Ishikawa cell lines using shRNA (Fig. 2A). CCK-8 assay results demonstrated that knockdown of LINC01224 (shLINC01224#1 and shLINC01224#2) decreased proliferation of HEC1A and Ishikawa cells in a time-dependent manner (Fig. 2B); this was only significant at 96 h. Colony formation assay indicated that LINC01224 knockdown
decreased the number of colonies of HEC1A and Ishikawa cells (Fig. 2C). Moreover, flow cytometry assay showed that apoptosis of HEC1A and Ishikawa cells transfected with shLINC01224 significantly increased compared with the sh‑con group (Fig. 2D). Western blotting results showed that knockdown of LINC01224 increased the protein levels of...
LINC01224 promotes proliferation and inhibits apoptosis of EC cells via sponging miR-485-5p. To investigate the role of LINC01224 in EC progression, LINC01224 was knocked down in HEC1A and Ishikawa cells (Fig. 4A) and miR-485-5p expression levels were assessed. Knockdown of LINC01224 significantly increased the expression of miR-485-5p; this was partially rescued by treatment with miR-485-5p inhibitor (Figs. 4A and S1F). Based on the aforementioned results, it was hypothesized that the LINC01224/miR-485-5p axis is linked to EC progression. CCK-8 and colony formation assays showed that LINC01224 knockdown inhibited the proliferation of HEC1A and Ishikawa cells but miR-485-5p inhibitor treatment partially reversed this effect (Fig. 4B and C). Flow cytometry assay displayed a similar result for EC cell apoptosis (Fig. 4D), consistent with western blotting results demonstrating that miR-485-5p inhibition restored the increased protein levels of cleaved caspase-3 and decreased protein levels of Bcl-2 and PCNA in EC cells transfected with shLINC01224 (Fig. S3).

Taken together, these results demonstrated that LINC01224 promoted proliferation and inhibited apoptosis of EC cells via sponging miR-485-5p.

LINC01224 elevates AKT3 expression via sponging miR-485-5p in EC cells. Previous research has demonstrated that AKT3 is a potential target of miRNA (19,20). It has been reported that lncRNAs serve as competing endogenous RNAs that interact with miRNAs to regulate the expression of key oncogenes (21), involved in tumorigenesis (21). The present study demonstrated that miR-485-5p bound to LINC01224. Starbase 3.0 predicted that miR-485-5p targets the 3'UTR of
Figure 4. LINC01224 promotes proliferation and inhibits apoptosis of endometrial carcinoma cells via sponging miR-485-5p. (A) Reverse transcription-quantitative PCR analysis was performed to determine miR-485-5p expression in HEC1A and Ishikawa cells transfected with sh-con, shLINC01224#1 or shLINC01224#1 + miR-485-5p inhibitor. (B) Cell Counting Kit-8 and (C) colony formation assays were used to measure the proliferation of HEC1A and Ishikawa cells transfected with sh-con, shLINC01224#1 or shLINC01224#1 + miR-485-5p inhibitor. (D) Cell apoptosis was determined by Annexin V/PI staining using flow cytometry analysis. Data are representative of three independent experiments and shown as the mean ± SD. **P<0.01. miR, microRNA; sh, short hairpin; con, control; OD, optical density.
Zuo et al.: LINC01224 promotes endometrial carcinoma by regulating miR-485-5p/AKT3

Discussion

EC is the most common cancer in women, but overall clinical outcomes are still unsatisfactory due to the lack of effective therapeutic targets (1-3). Increasing evidence has demonstrated that IncRNAs function as endogenous miRNA sponges by binding to miRNAs and regulating their function, thus participating in tumor initiation and progression, thus presenting potential therapeutic targets and prognostic biomarkers for cancer (6,9,10,16,22). A novel IncRNA, LINC01224, has been discovered to exhibit a tumor-promoting effect in cancer (including hepatocellular carcinoma and ovarian cancer) via miRNA-mediated target gene expression (12,13). However, its clinical significance and underlying functional role of LINC01224 in EC remain unclear. The present study demonstrated that expression of LINC01224 was significantly upregulated in EC tissue and cell lines; this was associated with shorter survival time of patients with EC. Knockdown of LINC01224 impaired EC cell proliferation but promoted apoptosis. The nude mouse xenograft model of LINC01224 knockdown further revealed that LINC01224 increased EC tumor growth in vivo. These results suggested that LINC01224 functioned as an oncogene to promote EC progression.

The involvement of miRNAs in cancer and their significance as clinical biomarkers is increasingly appreciated (14,23). miR-485-5p has been recently found to be downregulated in cancer, including cholangiocarcinoma, hepatocellular carcinoma and breast and lung cancer, and its low expression is positively associated with risk and poor prognosis of cancer, implying that miR-485-5p serves as a tumor suppressor (24-28). AKT3 has been found to mediate resistance to apoptosis in B-RAF-targeted melanoma cells (29). In the present study, bioinformatics analysis (Starbase 3.0) predicted that miR-485-5p was the only downstream miRNA

the AKT3 gene (Fig. 5A). Thus, AKT3 was selected for subsequent analysis. Luciferase reporter assay demonstrated that miR-485-5p mimics significantly inhibited luciferase activity of AKT3 WT; this effect was diminished following mutation of the predicted binding site for miR-485-5p (Fig. 5A), confirming the physical interaction of AKT3 with miR-485-5p. Both the mRNA and protein levels of AKT3 in HEC1A and Ishikawa cells were downregulated by overexpression of miR-485-5p mimics (Fig. 5B). Furthermore, knockdown of LINC01224 significantly decreased AKT3 protein and mRNA levels, which were effectively restored by miR-485-5p inhibitor (Fig. 5C). Collectively, these results indicated that LINC01224 elevated AKT3 expression via sponging miR-485-5p in EC cells.

Figure 5. LINC01224 elevates AKT3 expression via sponging miR-485-5p in endometrial carcinoma cells. (A) Predicted binding site of miR-485-5p within AKT3 using Starbase 3.0. Luciferase activity was determined in HEC1A and Ishikawa cells transfected with miR-485-5p mimics or miR-NC. Binding sequences in AKT3 WT were mutated to generate AKT MT. (B) Western blot and reverse transcription-quantitative PCR analysis were performed to determine AKT3 expression in HEC1A and Ishikawa cells transfected with (B) miR-NC or miR-485-5p mimics and (C) sh-con, shLINC01224#1 or shLINC01224#1 + miR-485-5p inhibitor. Data are presented as the mean of three independent experiments and shown as the mean ± SD. "P<0.01 vs. miR-NC. miR, microRNA; NC, negative control; MT, mutant; WT, wild-type; sh, short hairpin; con, control.
target of LINC01224. RNA pull-down and luciferase assays further verified their direct interaction in EC. Additionally, AKT3 was shown to be a direct target of miR-485-5p in EC cells. Functionally, LINC01224 inhibition significantly suppressed EC cell proliferation but increased apoptosis via sponging miR-485-5p; these effects were partially abrogated by miR-485-5p inhibition. Collectively, the present study determined the expression levels, clinical implication and functional mechanism of LINC01224 in EC and revealed that LINC01224 facilitated EC progression via mediating the miR-485-5p/AKT3 axis, thus offering a potential diagnostic biomarker and therapeutic target for EC treatment.

In summary, LINC01224 served as an oncogenic IncRNA to promote EC cell proliferation and inhibit apoptosis via sponging miR-485-5p to elevate AKT3 expression levels, thus promising a promising therapeutic target for EC treatment.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Affiliated Yixing Hospital of Jiangsu University.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
XZ, WL, XY and HZ conceived and supervised the project. XZ, WL, XY, TM, YR, MH, HY, HW and HZ performed the biological experiments. XZ, WL, XY and HZ analyzed data and wrote the manuscript. XY and HZ confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the ethics committee of the Affiliated Yixing Hospital of Jiangsu University.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References